Study shows Gardasil guards against vaginal, vulval cancers; Arizona lawmakers block debate over vaccine

Share this article:
The results of an international study appearing this week in the journal The Lancet show that Merck’s cervical cancer vaccine Gardasil also protects women against vulval and vaginal cancers. The findings seem to confirm that the human papillomavirus (HPV), which is responsible for virtually all cases of cervical cancer, is also responsible for many cases of vulval and vaginal cancer. HPV is present in 80% of the 6,000 cases of vulval and vaginal cancer cases diagnosed in the US each year, according to the study. The findings of the study were first presented at a meeting of the American Society of Clinical Oncology last year. Although less common than cervical cancer, vulval and vaginal cancers are becoming more widespread. The incidence of in situ carcinoma increased more than 400% in the US between 1973 and 2000. Invasive vulval cancer increased by 20% during the same period. Merck’s Gardasil was developed to target four strains of HPV, two of which (HPV 16 and 18) are linked to cervical cancer and to vulval cancer, and two (HPV 6 and 11) which cause anogenital warts. In other Gardasil related news, State lawmakers in Arizona made a pre-emptive move to block health officials in that state from mandating teenage girls to receive the vaccine, The Arizona Republic reports. The Arizona Senate has inserted an unusual prohibition in its bipartisan budget proposal to prevent health officials from debating the merits of making the vaccine mandatory for schoolchildren. It would prevent Arizona health officials from even having the conversation. State health officials, who have the authority under state law to decide which vaccine to require, say the prohibition is unnecessary. The vaccine is not even on the list of those they will consider requiring in coming years. But some would like to have the option eventually and worry that the Senate move sets a dangerous precedent.
Share this article:

Email Newsletters

More in News

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...

Pfizer Q2 sales slip, but still beat expectations

Pfizer Q2 sales slip, but still beat expectations

Patent losses and lost co-promotion agreements put a dent in sales.

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?